Nedosiran: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

19 March 2024

23 February 2024

  • curprev 21:3621:36, 23 February 2024‎ Kosar Doraghi talk contribs‎ 8,159 bytes +8,159‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=nedosiran |aOrAn=an |drugClass=LDHA-directed small interfering RNA |indicationType=treatment |indication=lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥ 30 mL/min/1.73 m2 |adverseReactions=injection site reactions |fdaLIADAdult=RIVFLOZA Injection 160 mg/mL is a clear, colorless-t..."
Retrieved from "https://www.wikidoc.org/index.php/Nedosiran"